×
Cyclo Therapeutics Total Long-Term Assets 2010-2024 | CYTH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cyclo Therapeutics total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
View More
Cyclo Therapeutics Total Long-Term Assets 2010-2024 | CYTH
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Cyclo Therapeutics total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$158.3B
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.6B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.1B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B